A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-12

AUTHORS

Adam Platt, John Morten, Qunsheng Ji, Paul Elvin, Chris Womack, Xinying Su, Emma Donald, Neil Gray, Jessica Read, Graham Bigley, Laura Blockley, Carl Cresswell, Angela Dale, Amanda Davies, Tianwei Zhang, Shuqiong Fan, Haihua Fu, Amanda Gladwin, Grace Harrod, James Stevens, Victoria Williams, Qingqing Ye, Li Zheng, Richard de Boer, Roy S Herbst, Jin-Soo Lee, James Vasselli

ABSTRACT

BACKGROUND: To determine the prevalence of RET rearrangement genes, RET copy number gains and expression in tumor samples from four Phase III non-small-cell lung cancer (NSCLC) trials of vandetanib, a selective inhibitor of VEGFR, RET and EGFR signaling, and to determine any association with outcome to vandetanib treatment. METHODS: Archival tumor samples from the ZODIAC ( NCT00312377 , vandetanib ± docetaxel), ZEAL ( NCT00418886 , vandetanib ± pemetrexed), ZEPHYR ( NCT00404924 , vandetanib vs placebo) and ZEST ( NCT00364351 , vandetanib vs erlotinib) studies were evaluated by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in 944 and 1102 patients. RESULTS: The prevalence of RET rearrangements by FISH was 0.7% (95% CI 0.3-1.5%) among patients with a known result. Seven tumor samples were positive for RET rearrangements (vandetanib, n = 3; comparator, n = 4). 2.8% (n = 26) of samples had RET amplification (innumerable RET clusters, or ≥7 copies in > 10% of tumor cells), 8.1% (n = 76) had low RET gene copy number gain (4-6 copies in ≥40% of tumor cells) and 8.3% (n = 92) were RET expression positive (signal intensity ++ or +++ in >10% of tumor cells). Of RET-rearrangement-positive patients, none had an objective response in the vandetanib arm and one patient responded in the comparator arm. Radiologic evidence of tumor shrinkage was observed in two patients treated with vandetanib and one treated with comparator drug. The objective response rate was similar in the vandetanib and comparator arms for patients positive for RET copy number gains or RET protein expression. CONCLUSIONS: We have identified prevalence for three RET biomarkers in a population predominated by non-Asians and smokers. RET rearrangement prevalence was lower than previously reported. We found no evidence of a differential benefit for efficacy by IHC and RET gene copy number gains. The low prevalence of RET rearrangements (0.7%) prevents firm conclusions regarding association of vandetanib treatment with efficacy in the RET rearrangement NSCLC subpopulation. TRIAL REGISTRATION: Randomized Phase III clinical trials ( NCT00312377 , ZODIAC; NCT00418886 , ZEAL; NCT00364351 , ZEST; NCT00404924 , ZEPHYR). More... »

PAGES

171

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-015-1146-8

DOI

http://dx.doi.org/10.1186/s12885-015-1146-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1014779199

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25881079


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Non-Small-Cell Lung", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Amplification", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Piperidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prevalence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-ret", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quinazolines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Translocation, Genetic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, da Vinci Building, Melbourn Science Park, Cambridge Road, Melbourn, SG8 6HB, Royston, Hertfordshire, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Platt", 
        "givenName": "Adam", 
        "id": "sg:person.01034244476.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034244476.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morten", 
        "givenName": "John", 
        "id": "sg:person.014307457674.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014307457674.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Innovation Cancer Center, AstraZeneca R&D, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ji", 
        "givenName": "Qunsheng", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Elvin", 
        "givenName": "Paul", 
        "id": "sg:person.01125017710.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125017710.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Womack", 
        "givenName": "Chris", 
        "id": "sg:person.01173133110.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173133110.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Innovation Cancer Center, AstraZeneca R&D, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Su", 
        "givenName": "Xinying", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Donald", 
        "givenName": "Emma", 
        "id": "sg:person.01253601301.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253601301.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gray", 
        "givenName": "Neil", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Read", 
        "givenName": "Jessica", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bigley", 
        "givenName": "Graham", 
        "id": "sg:person.01225342041.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225342041.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Blockley", 
        "givenName": "Laura", 
        "id": "sg:person.01050462340.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050462340.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cresswell", 
        "givenName": "Carl", 
        "id": "sg:person.0662375405.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662375405.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dale", 
        "givenName": "Angela", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Davies", 
        "givenName": "Amanda", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Innovation Cancer Center, AstraZeneca R&D, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Tianwei", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Innovation Cancer Center, AstraZeneca R&D, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fan", 
        "givenName": "Shuqiong", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Innovation Cancer Center, AstraZeneca R&D, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fu", 
        "givenName": "Haihua", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gladwin", 
        "givenName": "Amanda", 
        "id": "sg:person.01266635025.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266635025.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Harrod", 
        "givenName": "Grace", 
        "id": "sg:person.01241656537.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01241656537.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stevens", 
        "givenName": "James", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Williams", 
        "givenName": "Victoria", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Innovation Cancer Center, AstraZeneca R&D, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ye", 
        "givenName": "Qingqing", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Innovation Cancer Center, AstraZeneca R&D, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zheng", 
        "givenName": "Li", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Western Hospital", 
          "id": "https://www.grid.ac/institutes/grid.417075.0", 
          "name": [
            "Department of Hematology & Medical Oncology, Western Hospital, Melbourne, Victoria, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Boer", 
        "givenName": "Richard", 
        "id": "sg:person.0636147734.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636147734.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Yale Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.433818.5", 
          "name": [
            "Yale Comprehensive Cancer Center, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Herbst", 
        "givenName": "Roy S", 
        "id": "sg:person.01150737671.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150737671.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.410914.9", 
          "name": [
            "National Cancer Center, Goyang, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Jin-Soo", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "AstraZeneca, Wilmington, DE, USA", 
            "Current address \u2013 MedImmune, Gaithersburg, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vasselli", 
        "givenName": "James", 
        "id": "sg:person.01310421443.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310421443.70"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2010.28.5981", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000100366"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.lungcan.2013.07.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001739222"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.lungcan.2013.07.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001739222"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jto.0b013e31828a4d07", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001925332"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-12-0838", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002158930"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-12-0838", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002158930"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/cr.2012.27", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004383808", 
          "https://doi.org/10.1038/cr.2012.27"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.27940", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005873179"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/2159-8290.cd-13-0035", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006314777"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/2159-8290.cd-13-0035", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006314777"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.42.9829", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008924255"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.29.5717", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013535496"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.36.1709", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014560769"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.44.1477", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015188906"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.44.1477", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015188906"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.91.4.1579", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019071287"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/363458a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019766488", 
          "https://doi.org/10.1038/363458a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.2673", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028758097", 
          "https://doi.org/10.1038/nm.2673"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jto.0b013e3182721ed1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032942774"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.2644", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034280993", 
          "https://doi.org/10.1038/nm.2644"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.2644", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034280993", 
          "https://doi.org/10.1038/nm.2644"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.2644", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034280993", 
          "https://doi.org/10.1038/nm.2644"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.2644", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034280993", 
          "https://doi.org/10.1038/nm.2644"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.2658", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040612411", 
          "https://doi.org/10.1038/nm.2658"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.2658", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040612411", 
          "https://doi.org/10.1038/nm.2658"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cam4.13", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041196518"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1101/gr.133645.111", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041486412"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-12-3898", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047932956"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(10)70132-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052718381"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/hmg/2.7.851", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059644513"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jc.2007-1714", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064290203"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/or.2012.1908", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071531954"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/or.2012.1908", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071531954"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075108930", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075208258", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076464895", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-12", 
    "datePublishedReg": "2015-12-01", 
    "description": "BACKGROUND: To determine the prevalence of RET rearrangement genes, RET copy number gains and expression in tumor samples from four Phase III non-small-cell lung cancer (NSCLC) trials of vandetanib, a selective inhibitor of VEGFR, RET and EGFR signaling, and to determine any association with outcome to vandetanib treatment.\nMETHODS: Archival tumor samples from the ZODIAC ( NCT00312377 , vandetanib \u00b1 docetaxel), ZEAL ( NCT00418886 , vandetanib \u00b1 pemetrexed), ZEPHYR ( NCT00404924 , vandetanib vs placebo) and ZEST ( NCT00364351 , vandetanib vs erlotinib) studies were evaluated by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in 944 and 1102 patients.\nRESULTS: The prevalence of RET rearrangements by FISH was 0.7% (95% CI 0.3-1.5%) among patients with a known result. Seven tumor samples were positive for RET rearrangements (vandetanib, n = 3; comparator, n = 4). 2.8% (n = 26) of samples had RET amplification (innumerable RET clusters, or \u22657 copies in > 10% of tumor cells), 8.1% (n = 76) had low RET gene copy number gain (4-6 copies in \u226540% of tumor cells) and 8.3% (n = 92) were RET expression positive (signal intensity ++ or +++ in >10% of tumor cells). Of RET-rearrangement-positive patients, none had an objective response in the vandetanib arm and one patient responded in the comparator arm. Radiologic evidence of tumor shrinkage was observed in two patients treated with vandetanib and one treated with comparator drug. The objective response rate was similar in the vandetanib and comparator arms for patients positive for RET copy number gains or RET protein expression.\nCONCLUSIONS: We have identified prevalence for three RET biomarkers in a population predominated by non-Asians and smokers. RET rearrangement prevalence was lower than previously reported. We found no evidence of a differential benefit for efficacy by IHC and RET gene copy number gains. The low prevalence of RET rearrangements (0.7%) prevents firm conclusions regarding association of vandetanib treatment with efficacy in the RET rearrangement NSCLC subpopulation.\nTRIAL REGISTRATION: Randomized Phase III clinical trials ( NCT00312377 , ZODIAC; NCT00418886 , ZEAL; NCT00364351 , ZEST; NCT00404924 , ZEPHYR).", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12885-015-1146-8", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "name": "A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies", 
    "pagination": "171", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "46696ef0d0027c39820e277359a9a86385a22fa4eb2da8308fc04fe3d0941221"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25881079"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-015-1146-8"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1014779199"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-015-1146-8", 
      "https://app.dimensions.ai/details/publication/pub.1014779199"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:57", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89807_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2Fs12885-015-1146-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-015-1146-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-015-1146-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-015-1146-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-015-1146-8'


 

This table displays all metadata directly associated to this object as RDF triples.

407 TRIPLES      21 PREDICATES      71 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-015-1146-8 schema:about N0d3f7b82ef79491a9880f80979e6c137
2 N15ccdda570794cb29e9b906afd3837d0
3 N530c93099e9a49a2ba31377374d4389f
4 N538c055f8c9245ae98203aa78e4a2050
5 N559b3e3b1f7e471cbb4b0ce40b414822
6 N5afc2048960245349c948b989974b86c
7 N785e91144b0a4428a0d61b6868dda098
8 N79df45585793401abf905b449addf19b
9 N845e7fcef32645fab4b6c5ce30ca3050
10 Naece2318d73e4018a159db76e21b230c
11 Nb9231001d80b4775bde61e87f2740890
12 Nbae5ca15ccc142db8e62d2216ffe92de
13 Nd6014d4e59324e61aa1a7ceacac2630e
14 Ne7cadc0a62714db694855d78603bf89e
15 Nf7c634b7f77645d985dfebfc028050c9
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author Nb094ced63fe34d608841c9d4a60cd87d
19 schema:citation sg:pub.10.1038/363458a0
20 sg:pub.10.1038/cr.2012.27
21 sg:pub.10.1038/nm.2644
22 sg:pub.10.1038/nm.2658
23 sg:pub.10.1038/nm.2673
24 https://app.dimensions.ai/details/publication/pub.1075108930
25 https://app.dimensions.ai/details/publication/pub.1075208258
26 https://app.dimensions.ai/details/publication/pub.1076464895
27 https://doi.org/10.1002/cam4.13
28 https://doi.org/10.1002/cncr.27940
29 https://doi.org/10.1016/j.lungcan.2013.07.009
30 https://doi.org/10.1016/s1470-2045(10)70132-7
31 https://doi.org/10.1073/pnas.91.4.1579
32 https://doi.org/10.1093/hmg/2.7.851
33 https://doi.org/10.1097/jto.0b013e3182721ed1
34 https://doi.org/10.1097/jto.0b013e31828a4d07
35 https://doi.org/10.1101/gr.133645.111
36 https://doi.org/10.1158/1078-0432.ccr-12-0838
37 https://doi.org/10.1158/1078-0432.ccr-12-3898
38 https://doi.org/10.1158/2159-8290.cd-13-0035
39 https://doi.org/10.1200/jco.2010.28.5981
40 https://doi.org/10.1200/jco.2010.29.5717
41 https://doi.org/10.1200/jco.2011.36.1709
42 https://doi.org/10.1200/jco.2012.42.9829
43 https://doi.org/10.1200/jco.2012.44.1477
44 https://doi.org/10.1210/jc.2007-1714
45 https://doi.org/10.3892/or.2012.1908
46 schema:datePublished 2015-12
47 schema:datePublishedReg 2015-12-01
48 schema:description BACKGROUND: To determine the prevalence of RET rearrangement genes, RET copy number gains and expression in tumor samples from four Phase III non-small-cell lung cancer (NSCLC) trials of vandetanib, a selective inhibitor of VEGFR, RET and EGFR signaling, and to determine any association with outcome to vandetanib treatment. METHODS: Archival tumor samples from the ZODIAC ( NCT00312377 , vandetanib ± docetaxel), ZEAL ( NCT00418886 , vandetanib ± pemetrexed), ZEPHYR ( NCT00404924 , vandetanib vs placebo) and ZEST ( NCT00364351 , vandetanib vs erlotinib) studies were evaluated by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in 944 and 1102 patients. RESULTS: The prevalence of RET rearrangements by FISH was 0.7% (95% CI 0.3-1.5%) among patients with a known result. Seven tumor samples were positive for RET rearrangements (vandetanib, n = 3; comparator, n = 4). 2.8% (n = 26) of samples had RET amplification (innumerable RET clusters, or ≥7 copies in > 10% of tumor cells), 8.1% (n = 76) had low RET gene copy number gain (4-6 copies in ≥40% of tumor cells) and 8.3% (n = 92) were RET expression positive (signal intensity ++ or +++ in >10% of tumor cells). Of RET-rearrangement-positive patients, none had an objective response in the vandetanib arm and one patient responded in the comparator arm. Radiologic evidence of tumor shrinkage was observed in two patients treated with vandetanib and one treated with comparator drug. The objective response rate was similar in the vandetanib and comparator arms for patients positive for RET copy number gains or RET protein expression. CONCLUSIONS: We have identified prevalence for three RET biomarkers in a population predominated by non-Asians and smokers. RET rearrangement prevalence was lower than previously reported. We found no evidence of a differential benefit for efficacy by IHC and RET gene copy number gains. The low prevalence of RET rearrangements (0.7%) prevents firm conclusions regarding association of vandetanib treatment with efficacy in the RET rearrangement NSCLC subpopulation. TRIAL REGISTRATION: Randomized Phase III clinical trials ( NCT00312377 , ZODIAC; NCT00418886 , ZEAL; NCT00364351 , ZEST; NCT00404924 , ZEPHYR).
49 schema:genre research_article
50 schema:inLanguage en
51 schema:isAccessibleForFree true
52 schema:isPartOf Nee828a53c6bc4c78b495abeef9cfbd7d
53 Nf1c241ce2159433a9644191c738d5d32
54 sg:journal.1024632
55 schema:name A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies
56 schema:pagination 171
57 schema:productId N563f9c0a4d344e5ea430ce376771ff4d
58 N802856f19d1c4689a80cc2adceaf0b9a
59 N89e7dc6aa6434537ab463335477def19
60 Na7e3e43db3d94987b8b7d23396871b7e
61 Nd466d3e7f65a41f9a00eb3d42e297068
62 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014779199
63 https://doi.org/10.1186/s12885-015-1146-8
64 schema:sdDatePublished 2019-04-11T09:57
65 schema:sdLicense https://scigraph.springernature.com/explorer/license/
66 schema:sdPublisher N110f252d2cd04c41ad62dbab94669958
67 schema:url http://link.springer.com/10.1186%2Fs12885-015-1146-8
68 sgo:license sg:explorer/license/
69 sgo:sdDataset articles
70 rdf:type schema:ScholarlyArticle
71 N040a450dbc7f4bcb91bdce858c87feb7 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
72 schema:familyName Read
73 schema:givenName Jessica
74 rdf:type schema:Person
75 N0cefa954d15941c4ad3a526a7b5b0699 rdf:first sg:person.01266635025.79
76 rdf:rest N6b2223c5899a47db88b5d9db763b5e41
77 N0d3f7b82ef79491a9880f80979e6c137 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Quinazolines
79 rdf:type schema:DefinedTerm
80 N110f252d2cd04c41ad62dbab94669958 schema:name Springer Nature - SN SciGraph project
81 rdf:type schema:Organization
82 N15062632e2b24ddcbbde0feb36dda05f rdf:first N8b53ca101e7b4d24b2824674bbbe4101
83 rdf:rest Nd68e03f9b7d046578a2b351ac5e31c12
84 N15ccdda570794cb29e9b906afd3837d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Male
86 rdf:type schema:DefinedTerm
87 N1b088eedb6fe408796b8f67ca39d7308 schema:name Innovation Cancer Center, AstraZeneca R&D, Shanghai, China
88 rdf:type schema:Organization
89 N1c81881f0ee04fd9836f2048b20f7c54 rdf:first Ne29952cd58404c1d8e1b223e0048fff7
90 rdf:rest N57f65042d6cb4eb59bb36cc3dd15541e
91 N24da7525251448d3bf5ab62ba941084c rdf:first Nbf888b19372f4d4ea5e7694a55a75ee6
92 rdf:rest N87edbe8e718a496287aa7402d58be8cb
93 N2bc4abf1371147b4b4339c7a536191a3 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
94 schema:familyName Dale
95 schema:givenName Angela
96 rdf:type schema:Person
97 N37083d5725ec4d6eb3e34639f6f6e87d rdf:first Nc833f9cb59ae48f6958bc76c30b1f4f5
98 rdf:rest N587e368168d647b4a5717e70dee648c3
99 N40f4e8e0e2c3419b87f4033ea723fa14 rdf:first sg:person.0636147734.20
100 rdf:rest N8ccd9b8dc15d4204973c275eabb3eb3e
101 N50e4ccaf87ee4d638c0dd204193edb55 schema:name Innovation Cancer Center, AstraZeneca R&D, Shanghai, China
102 rdf:type schema:Organization
103 N530c93099e9a49a2ba31377374d4389f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Treatment Outcome
105 rdf:type schema:DefinedTerm
106 N538c055f8c9245ae98203aa78e4a2050 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Translocation, Genetic
108 rdf:type schema:DefinedTerm
109 N548909d40311400c8e3cbc11b2f01642 schema:name Innovation Cancer Center, AstraZeneca R&D, Shanghai, China
110 rdf:type schema:Organization
111 N54eca13bee4447f29cba301e5815a777 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
112 schema:familyName Davies
113 schema:givenName Amanda
114 rdf:type schema:Person
115 N559b3e3b1f7e471cbb4b0ce40b414822 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Humans
117 rdf:type schema:DefinedTerm
118 N563f9c0a4d344e5ea430ce376771ff4d schema:name readcube_id
119 schema:value 46696ef0d0027c39820e277359a9a86385a22fa4eb2da8308fc04fe3d0941221
120 rdf:type schema:PropertyValue
121 N57f65042d6cb4eb59bb36cc3dd15541e rdf:first N586d29375ea04c76b773e50c7de6b644
122 rdf:rest N8286bec17c4449bfa7a55df03480962f
123 N586d29375ea04c76b773e50c7de6b644 schema:affiliation Nfba4575b23134249ac67007c9cd220f3
124 schema:familyName Ye
125 schema:givenName Qingqing
126 rdf:type schema:Person
127 N587e368168d647b4a5717e70dee648c3 rdf:first Nbb3f90367ae74beabc3521496f40d948
128 rdf:rest Nc84b25b3298b4106832c28bc707376b6
129 N5afc2048960245349c948b989974b86c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Piperidines
131 rdf:type schema:DefinedTerm
132 N5ea4b0dd43db4be9915e88a10e998535 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
133 schema:familyName Stevens
134 schema:givenName James
135 rdf:type schema:Person
136 N5f19a344da95494aa655e2bb4321f12e rdf:first Nb1787b60eb804aadbfebcb15c0c482a1
137 rdf:rest N8be47288ce524dfbb9f712dbcf7110cd
138 N64203f1f019b45909f4672e86d794b1a rdf:first N5ea4b0dd43db4be9915e88a10e998535
139 rdf:rest N1c81881f0ee04fd9836f2048b20f7c54
140 N660050f22c7847a986383ba9f2fe146c rdf:first sg:person.014307457674.87
141 rdf:rest N15062632e2b24ddcbbde0feb36dda05f
142 N69d40db7223549eaa13a609daf70afa1 rdf:first sg:person.01225342041.57
143 rdf:rest Nf33aab242a434bb08cca4ed835d2b953
144 N6b2223c5899a47db88b5d9db763b5e41 rdf:first sg:person.01241656537.88
145 rdf:rest N64203f1f019b45909f4672e86d794b1a
146 N72c96eb3d6e642509e20b90dfd331542 schema:affiliation N1b088eedb6fe408796b8f67ca39d7308
147 schema:familyName Zheng
148 schema:givenName Li
149 rdf:type schema:Person
150 N74dcd7bd2e1e4c729ed655cf07305f77 schema:name Innovation Cancer Center, AstraZeneca R&D, Shanghai, China
151 rdf:type schema:Organization
152 N785e91144b0a4428a0d61b6868dda098 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Carcinoma, Non-Small-Cell Lung
154 rdf:type schema:DefinedTerm
155 N79df45585793401abf905b449addf19b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Middle Aged
157 rdf:type schema:DefinedTerm
158 N802856f19d1c4689a80cc2adceaf0b9a schema:name doi
159 schema:value 10.1186/s12885-015-1146-8
160 rdf:type schema:PropertyValue
161 N8286bec17c4449bfa7a55df03480962f rdf:first N72c96eb3d6e642509e20b90dfd331542
162 rdf:rest N40f4e8e0e2c3419b87f4033ea723fa14
163 N845e7fcef32645fab4b6c5ce30ca3050 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Lung Neoplasms
165 rdf:type schema:DefinedTerm
166 N87edbe8e718a496287aa7402d58be8cb rdf:first sg:person.01253601301.22
167 rdf:rest Nab19f0695f3c46b58e0f07055905cade
168 N89e7dc6aa6434537ab463335477def19 schema:name nlm_unique_id
169 schema:value 100967800
170 rdf:type schema:PropertyValue
171 N8b53ca101e7b4d24b2824674bbbe4101 schema:affiliation N8e1e3a2d822e4eb0a3a56834f2856ed3
172 schema:familyName Ji
173 schema:givenName Qunsheng
174 rdf:type schema:Person
175 N8be47288ce524dfbb9f712dbcf7110cd rdf:first sg:person.01310421443.70
176 rdf:rest rdf:nil
177 N8ccd9b8dc15d4204973c275eabb3eb3e rdf:first sg:person.01150737671.46
178 rdf:rest N5f19a344da95494aa655e2bb4321f12e
179 N8e1e3a2d822e4eb0a3a56834f2856ed3 schema:name Innovation Cancer Center, AstraZeneca R&D, Shanghai, China
180 rdf:type schema:Organization
181 N9018d516f9d941cb96a2893176d9068b rdf:first N040a450dbc7f4bcb91bdce858c87feb7
182 rdf:rest N69d40db7223549eaa13a609daf70afa1
183 N91fa249a5e73467ea93cf50ec86ab02b schema:affiliation N548909d40311400c8e3cbc11b2f01642
184 schema:familyName Fu
185 schema:givenName Haihua
186 rdf:type schema:Person
187 N9c14b47ee5694010b293e5ce6c171f4a rdf:first N2bc4abf1371147b4b4339c7a536191a3
188 rdf:rest Necc82fdbdd8645bd9cd27c82173b9f5b
189 Na7e3e43db3d94987b8b7d23396871b7e schema:name pubmed_id
190 schema:value 25881079
191 rdf:type schema:PropertyValue
192 Nab19f0695f3c46b58e0f07055905cade rdf:first Nefc84c5f5b704c6698b6b5da74f6c401
193 rdf:rest N9018d516f9d941cb96a2893176d9068b
194 Nae0bfee474694addbf921e9ee51da52b rdf:first sg:person.01173133110.53
195 rdf:rest N24da7525251448d3bf5ab62ba941084c
196 Naece2318d73e4018a159db76e21b230c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Aged
198 rdf:type schema:DefinedTerm
199 Nb094ced63fe34d608841c9d4a60cd87d rdf:first sg:person.01034244476.04
200 rdf:rest N660050f22c7847a986383ba9f2fe146c
201 Nb1787b60eb804aadbfebcb15c0c482a1 schema:affiliation https://www.grid.ac/institutes/grid.410914.9
202 schema:familyName Lee
203 schema:givenName Jin-Soo
204 rdf:type schema:Person
205 Nb2e68b9b6ecb4e8b86deff8e11623fa0 schema:name Innovation Cancer Center, AstraZeneca R&D, Shanghai, China
206 rdf:type schema:Organization
207 Nb9231001d80b4775bde61e87f2740890 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Gene Amplification
209 rdf:type schema:DefinedTerm
210 Nbae5ca15ccc142db8e62d2216ffe92de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
211 schema:name Retrospective Studies
212 rdf:type schema:DefinedTerm
213 Nbb3f90367ae74beabc3521496f40d948 schema:affiliation N74dcd7bd2e1e4c729ed655cf07305f77
214 schema:familyName Fan
215 schema:givenName Shuqiong
216 rdf:type schema:Person
217 Nbf888b19372f4d4ea5e7694a55a75ee6 schema:affiliation N50e4ccaf87ee4d638c0dd204193edb55
218 schema:familyName Su
219 schema:givenName Xinying
220 rdf:type schema:Person
221 Nc833f9cb59ae48f6958bc76c30b1f4f5 schema:affiliation Nb2e68b9b6ecb4e8b86deff8e11623fa0
222 schema:familyName Zhang
223 schema:givenName Tianwei
224 rdf:type schema:Person
225 Nc84b25b3298b4106832c28bc707376b6 rdf:first N91fa249a5e73467ea93cf50ec86ab02b
226 rdf:rest N0cefa954d15941c4ad3a526a7b5b0699
227 Nd466d3e7f65a41f9a00eb3d42e297068 schema:name dimensions_id
228 schema:value pub.1014779199
229 rdf:type schema:PropertyValue
230 Nd6014d4e59324e61aa1a7ceacac2630e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
231 schema:name Female
232 rdf:type schema:DefinedTerm
233 Nd68e03f9b7d046578a2b351ac5e31c12 rdf:first sg:person.01125017710.16
234 rdf:rest Nae0bfee474694addbf921e9ee51da52b
235 Ndae438e07d6b4e8c8bb7373b3fcfdcaa rdf:first sg:person.0662375405.84
236 rdf:rest N9c14b47ee5694010b293e5ce6c171f4a
237 Ne29952cd58404c1d8e1b223e0048fff7 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
238 schema:familyName Williams
239 schema:givenName Victoria
240 rdf:type schema:Person
241 Ne7cadc0a62714db694855d78603bf89e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
242 schema:name Prevalence
243 rdf:type schema:DefinedTerm
244 Necc82fdbdd8645bd9cd27c82173b9f5b rdf:first N54eca13bee4447f29cba301e5815a777
245 rdf:rest N37083d5725ec4d6eb3e34639f6f6e87d
246 Nee828a53c6bc4c78b495abeef9cfbd7d schema:volumeNumber 15
247 rdf:type schema:PublicationVolume
248 Nefc84c5f5b704c6698b6b5da74f6c401 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
249 schema:familyName Gray
250 schema:givenName Neil
251 rdf:type schema:Person
252 Nf1c241ce2159433a9644191c738d5d32 schema:issueNumber 1
253 rdf:type schema:PublicationIssue
254 Nf33aab242a434bb08cca4ed835d2b953 rdf:first sg:person.01050462340.23
255 rdf:rest Ndae438e07d6b4e8c8bb7373b3fcfdcaa
256 Nf7c634b7f77645d985dfebfc028050c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
257 schema:name Proto-Oncogene Proteins c-ret
258 rdf:type schema:DefinedTerm
259 Nfba4575b23134249ac67007c9cd220f3 schema:name Innovation Cancer Center, AstraZeneca R&D, Shanghai, China
260 rdf:type schema:Organization
261 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
262 schema:name Medical and Health Sciences
263 rdf:type schema:DefinedTerm
264 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
265 schema:name Oncology and Carcinogenesis
266 rdf:type schema:DefinedTerm
267 sg:journal.1024632 schema:issn 1471-2407
268 schema:name BMC Cancer
269 rdf:type schema:Periodical
270 sg:person.01034244476.04 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
271 schema:familyName Platt
272 schema:givenName Adam
273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034244476.04
274 rdf:type schema:Person
275 sg:person.01050462340.23 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
276 schema:familyName Blockley
277 schema:givenName Laura
278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050462340.23
279 rdf:type schema:Person
280 sg:person.01125017710.16 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
281 schema:familyName Elvin
282 schema:givenName Paul
283 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125017710.16
284 rdf:type schema:Person
285 sg:person.01150737671.46 schema:affiliation https://www.grid.ac/institutes/grid.433818.5
286 schema:familyName Herbst
287 schema:givenName Roy S
288 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150737671.46
289 rdf:type schema:Person
290 sg:person.01173133110.53 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
291 schema:familyName Womack
292 schema:givenName Chris
293 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173133110.53
294 rdf:type schema:Person
295 sg:person.01225342041.57 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
296 schema:familyName Bigley
297 schema:givenName Graham
298 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225342041.57
299 rdf:type schema:Person
300 sg:person.01241656537.88 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
301 schema:familyName Harrod
302 schema:givenName Grace
303 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01241656537.88
304 rdf:type schema:Person
305 sg:person.01253601301.22 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
306 schema:familyName Donald
307 schema:givenName Emma
308 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253601301.22
309 rdf:type schema:Person
310 sg:person.01266635025.79 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
311 schema:familyName Gladwin
312 schema:givenName Amanda
313 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266635025.79
314 rdf:type schema:Person
315 sg:person.01310421443.70 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
316 schema:familyName Vasselli
317 schema:givenName James
318 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310421443.70
319 rdf:type schema:Person
320 sg:person.014307457674.87 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
321 schema:familyName Morten
322 schema:givenName John
323 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014307457674.87
324 rdf:type schema:Person
325 sg:person.0636147734.20 schema:affiliation https://www.grid.ac/institutes/grid.417075.0
326 schema:familyName de Boer
327 schema:givenName Richard
328 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636147734.20
329 rdf:type schema:Person
330 sg:person.0662375405.84 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
331 schema:familyName Cresswell
332 schema:givenName Carl
333 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662375405.84
334 rdf:type schema:Person
335 sg:pub.10.1038/363458a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019766488
336 https://doi.org/10.1038/363458a0
337 rdf:type schema:CreativeWork
338 sg:pub.10.1038/cr.2012.27 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004383808
339 https://doi.org/10.1038/cr.2012.27
340 rdf:type schema:CreativeWork
341 sg:pub.10.1038/nm.2644 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034280993
342 https://doi.org/10.1038/nm.2644
343 rdf:type schema:CreativeWork
344 sg:pub.10.1038/nm.2658 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040612411
345 https://doi.org/10.1038/nm.2658
346 rdf:type schema:CreativeWork
347 sg:pub.10.1038/nm.2673 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028758097
348 https://doi.org/10.1038/nm.2673
349 rdf:type schema:CreativeWork
350 https://app.dimensions.ai/details/publication/pub.1075108930 schema:CreativeWork
351 https://app.dimensions.ai/details/publication/pub.1075208258 schema:CreativeWork
352 https://app.dimensions.ai/details/publication/pub.1076464895 schema:CreativeWork
353 https://doi.org/10.1002/cam4.13 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041196518
354 rdf:type schema:CreativeWork
355 https://doi.org/10.1002/cncr.27940 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005873179
356 rdf:type schema:CreativeWork
357 https://doi.org/10.1016/j.lungcan.2013.07.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001739222
358 rdf:type schema:CreativeWork
359 https://doi.org/10.1016/s1470-2045(10)70132-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052718381
360 rdf:type schema:CreativeWork
361 https://doi.org/10.1073/pnas.91.4.1579 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019071287
362 rdf:type schema:CreativeWork
363 https://doi.org/10.1093/hmg/2.7.851 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059644513
364 rdf:type schema:CreativeWork
365 https://doi.org/10.1097/jto.0b013e3182721ed1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032942774
366 rdf:type schema:CreativeWork
367 https://doi.org/10.1097/jto.0b013e31828a4d07 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001925332
368 rdf:type schema:CreativeWork
369 https://doi.org/10.1101/gr.133645.111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041486412
370 rdf:type schema:CreativeWork
371 https://doi.org/10.1158/1078-0432.ccr-12-0838 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002158930
372 rdf:type schema:CreativeWork
373 https://doi.org/10.1158/1078-0432.ccr-12-3898 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047932956
374 rdf:type schema:CreativeWork
375 https://doi.org/10.1158/2159-8290.cd-13-0035 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006314777
376 rdf:type schema:CreativeWork
377 https://doi.org/10.1200/jco.2010.28.5981 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000100366
378 rdf:type schema:CreativeWork
379 https://doi.org/10.1200/jco.2010.29.5717 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013535496
380 rdf:type schema:CreativeWork
381 https://doi.org/10.1200/jco.2011.36.1709 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014560769
382 rdf:type schema:CreativeWork
383 https://doi.org/10.1200/jco.2012.42.9829 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008924255
384 rdf:type schema:CreativeWork
385 https://doi.org/10.1200/jco.2012.44.1477 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015188906
386 rdf:type schema:CreativeWork
387 https://doi.org/10.1210/jc.2007-1714 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064290203
388 rdf:type schema:CreativeWork
389 https://doi.org/10.3892/or.2012.1908 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071531954
390 rdf:type schema:CreativeWork
391 https://www.grid.ac/institutes/grid.410914.9 schema:alternateName National Cancer Center
392 schema:name National Cancer Center, Goyang, Republic of Korea
393 rdf:type schema:Organization
394 https://www.grid.ac/institutes/grid.417075.0 schema:alternateName Western Hospital
395 schema:name Department of Hematology & Medical Oncology, Western Hospital, Melbourne, Victoria, Australia
396 rdf:type schema:Organization
397 https://www.grid.ac/institutes/grid.417815.e schema:alternateName AstraZeneca (United Kingdom)
398 schema:name AstraZeneca, Macclesfield, UK
399 AstraZeneca, da Vinci Building, Melbourn Science Park, Cambridge Road, Melbourn, SG8 6HB, Royston, Hertfordshire, UK
400 rdf:type schema:Organization
401 https://www.grid.ac/institutes/grid.418152.b schema:alternateName AstraZeneca (United States)
402 schema:name AstraZeneca, Wilmington, DE, USA
403 Current address – MedImmune, Gaithersburg, MD, USA
404 rdf:type schema:Organization
405 https://www.grid.ac/institutes/grid.433818.5 schema:alternateName Yale Cancer Center
406 schema:name Yale Comprehensive Cancer Center, New Haven, CT, USA
407 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...